On September 28, 2020, the State Intellectual Property Office granted Shenzhen Yishi Kangning Biotechnology Co., Ltd. (Yoshi Kangning) an invention patent involving the company's core technology. The name of the patent is: "A recombinant adeno-associated virus vector carrying tumor-testis antigen 10 gene and its application value", the application number or patent number is: 201911061395.5, this patent is the 14th China obtained by ISKCON Patent.

Cancer-testis antigen 10 (CT10) belongs to the tumor-testis antigen (Cancer/testis antigen, CT antigen) family. Since CT10 was first found in melanoma cells, it is also called Melanoma antigen C2 (MAGE-C2). CT10 is not expressed in normal tissues of adults, but it is widely expressed in various malignant tumor tissues such as melanoma, lung cancer, liver cancer, prostate cancer, ovarian cancer, and sarcoma. Therefore, CT10 antigen is not only of great significance for the diagnosis, treatment effect and prognosis evaluation of malignant tumors, but also as an ideal precision target for targeted cellular immunotherapy (ACTL). Many years of clinical research and practice have proved that it is useful for enriching The treatment of ACTL is of great value to improve the efficacy.

The invention patent of "A recombinant adeno-associated virus vector carrying tumor-testis antigen 10 gene and its application value" is not only an affirmation of ISKCON’s independent innovation capability, but also the core of maintaining the independent intellectual property rights of my country and the company and maintaining its superiority Competitiveness is of great significance.

Ishikoning has always been guided by scientific and technological innovation, continuously increasing the research and development of products and anti-tumor targeted (precision) cellular immunotherapy technologies, and also attaches great importance to intellectual property protection and related patent applications. The company now has 14 Chinese invention patents, 3 American invention patents and 1 European invention patent. At present, more than 10 invention patents have entered the substantive examination stage of the State Intellectual Property Office. It is estimated that there will be nearly 50 invention patents in 5 years. At the same time, the company has more than 30 kinds of products produced in a large-scale and standardized manner. It is expected that the company will develop and produce more than 50 kinds of products within 5 years, which will contribute to the rapid development of anti-tumor targeted cellular immunotherapy with obvious characteristics of precision medicine in my country. power.